Skip to main content
Brock O'Neil
( out of 1218 reviews )

Brock O'Neil, MD

Languages spoken: English, Italian

Clinical Locations

Primary Location

Brock O’Neil, MD is an associate professor in the Division of Urology at the University of Utah School of Medicine and the Huntsman Cancer Institute. His clinical practice focuses on the surgical treatment of genitourinary malignancies including prostate, bladder, kidney, adrenal, testicular, penile and urethral cancers. He is an experienced robotic, laparoscopic, endoscopic, and open surgeon. Dr O’Neil completed medical school at the University of Rochester, residency at the University of Utah, and fellowship in Urologic Oncology at Vanderbilt University.

Board Certification

American Board of Urology

Patient Rating

Patients consistently describe Dr. O'Neil as knowledgeable, thorough, and professional, noting that he clearly explains diagnoses and treatment options in understandable language. Many commend his compassionate bedside manner, patient listening, and effort to include them in decision-making, which helps relieve anxiety. Reviewers also praise his follow-up and coordination of care, including effective virtual visits and supportive staff interactions.

Generated via Patient Reviews

4.9 /5
( out of 1218 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.


Sep 18, 2026
HUNTSMAN CANCER INSTITUTE

I only had a 15 minute zoom call with Dr. O'Neill. But we covered numerous options. He answered all the questions we had and and gave us insight into what we needed to do in the future. I was extremely satisfied with the professionalism and knowledge of Dr. O'Neill.

Sep 18, 2026
HUNTSMAN CANCER INSTITUTE

The team has been really helpful in guiding me through a very difficult time in my life.

Sep 18, 2026
HUNTSMAN CANCER INSTITUTE

If you seek treatment from Doctor O'Neil, you can rest assured that you will receive exceptional care.

Sep 17, 2026
HUNTSMAN CANCER INSTITUTE

Dr. O'Neil made the entire process as easy as it could be. His surgical work was top notch as well.

Sep 11, 2026
HUNTSMAN CANCER INSTITUTE

Highly recommend by outside Huntsman Urologist based on experience, knowledge, professionalism, schedule accountability and patient respect. ALL found to be spot on.

Jul 23, 2026
HUNTSMAN CANCER INSTITUTE

Professional

May 30, 2026
HUNTSMAN CANCER INSTITUTE

Dr. O'Neil is an engaging person who communicates well and has a deep understanding of his patients' needs. He presented me with options and explained the big picture with all the details that I need to make my decisions. We decided on a course that included meeting with another surgeon who will be joining the faculty in a few months. He really strove to make sure I had good information and provided me with insight that I could not have gotten from anyone else. Very good person and it was obvious to me he is a good doctor and surgeon.

May 30, 2026
HUNTSMAN CANCER INSTITUTE

Explained everything very experienced

May 25, 2026
HUNTSMAN CANCER INSTITUTE

I trust Dr. O'Neil implicitly. He is recognized as a gifted doctor and specialist in his field. He is also honest, caring, and careful to ensure that I understand the options available and the importance of each of those options. He made sure that I understood the next treatment phase and it's importance in ensuring that the cancer does not return. I feel totally confident in the quality of my care and my future outcome. I am so grateful to be able to access the highest quality of care available. When I evaluate the entire process, from a 360 perspective, every aspect of care is exceptional and it is the physician, along with his senior staff, who ensure that is the case. Thank you.

May 25, 2026
HUNTSMAN CANCER INSTITUTE

He put me on a path of becoming cancer free. I am very grateful for his care.

May 22, 2026
HUNTSMAN CANCER INSTITUTE

Dr. O'Neil is very good at explaining things and letting you ask all the questions you have. He didn't make me feel that he had to rush.

May 16, 2026
HUNTSMAN CANCER INSTITUTE

Great doctor

May 16, 2026
HUNTSMAN CANCER INSTITUTE

I really appreciate Dr O'Neil for his skill and knowledge. He is also caring and has time to answer any questions or concerns. I credit him and Huntsman for me being able to live the life I live.

May 15, 2026
HUNTSMAN CANCER INSTITUTE

He is very caring. He wants the best outcome for you. He'll talk with you about all your concerns. Him and his team are excellent.

May 08, 2026
HUNTSMAN CANCER INSTITUTE

Never met him, but he was great on the 2 virtuals we had

May 06, 2026
HUNTSMAN CANCER INSTITUTE

We totally recommend Dr. Brock O'Neil as a highly proficient doctor.

May 02, 2026
HUNTSMAN CANCER INSTITUTE

I feel I am in good hands and trust Dr. O'Neil to always treat me with respect and I feel he is treating my illness with the best medical care possible.

Apr 24, 2026
HUNTSMAN CANCER INSTITUTE

He seemed concerned with my well being. Very helpful.

Mar 20, 2026
HUNTSMAN CANCER INSTITUTE

Brock B O'Neil, MD is very gifted and has a very large practice. Yet, he sits down and answers questions. My husband and I really appreciated that.

Mar 17, 2026
HUNTSMAN CANCER INSTITUTE

He is very proffessional and displays confidence

Mar 16, 2026
HUNTSMAN CANCER INSTITUTE

Dr. O'Neil has a well-deserved excellent reputation in his field. He asked questions, provided me options, listened to me, explained what I can expect from the procedure. and suggested multiple follow-up opportunities for support.

Mar 15, 2026
HUNTSMAN CANCER INSTITUTE

We thought Dr. O'Neil was the best. It seems everyone we meet a new doctor they are even better than the last one. Everything Dr. O'Neil told us seemed like the right thing for us, at the right time. We will follow up with him as we go along this adventure.

Feb 14, 2026
HUNTSMAN CANCER INSTITUTE

I would wholeheartedly recommend him and his staff

Feb 07, 2026
HUNTSMAN CANCER INSTITUTE

Great Doctor! Can't say more!

Jan 24, 2026
HUNTSMAN CANCER INSTITUTE

I feel lucky to have Dr. O'Neil as my doctor.

Jan 22, 2026
HUNTSMAN CANCER INSTITUTE

He was nice and curtis He tells you the way is

Jan 16, 2026
HUNTSMAN CANCER INSTITUTE

He cares about his patience health.

Jan 16, 2026
HUNTSMAN CANCER INSTITUTE

He seemed very thorough and knowledgeable. He explained everything so we knew what was happening and how we would handle everything moving forward. Everything at Huntsman was very professional and caring and knowledgeable.

Jan 12, 2026
HUNTSMAN CANCER INSTITUTE

I think that he did his profession well

Jan 10, 2026
HUNTSMAN CANCER INSTITUTE

Dr. O'Neil and his staff are always so amazing, to have a child with Autism and having him go through this scary experience and process, you and your team help ease the stress he can have going through new changes and experiences. Thank you again for all you do

Jan 09, 2026
HUNTSMAN CANCER INSTITUTE

First rate Doctor.

Jan 08, 2026
HUNTSMAN CANCER INSTITUTE

Very caring and concerned about your overall health.

Dec 21, 2025
HUNTSMAN CANCER INSTITUTE

I have appreciated Dr. O 'Neal's k sledge and professionalism.

Dec 19, 2025
HUNTSMAN CANCER INSTITUTE

My PA was so informative, it helped relax me, to be able to make a plan of attack. Thank you for your sincere work ethic.

Dec 19, 2025
HUNTSMAN CANCER INSTITUTE

One of the best [TRANSLATED]

Dec 12, 2025
HUNTSMAN CANCER INSTITUTE

Very fast, efficient, and effective.

Dec 07, 2025
HUNTSMAN CANCER INSTITUTE

Exceptional Doctor!

Nov 22, 2025
HUNTSMAN CANCER INSTITUTE

Dr. O'Neil and his staff gave me excellent care and advice. He was very personable and concerned for my best welfare.

Nov 22, 2025
HUNTSMAN CANCER INSTITUTE

He is very knowledgeable, listens to our concerns, and is a very caring doctor.

Nov 21, 2025
HUNTSMAN CANCER INSTITUTE

Dr. O'Neil is an excellent surgeon and a very compassionate person.

Nov 21, 2025
HUNTSMAN CANCER INSTITUTE

I found him direct, but lacking in compassion. He spent 15 minutes and left.

Nov 18, 2025
HUNTSMAN CANCER INSTITUTE

Very attentive and listens carefully to all I said. I appreciate his overall interaction with me.

Nov 15, 2025
HUNTSMAN CANCER INSTITUTE

Dr O'Neil was very helpful. He explained several options to treatment, and included me in discussions about what would be best for my situation. I would highly recommend him as a choice for physician.

Nov 15, 2025
HUNTSMAN CANCER INSTITUTE

Very professional and compassionate. I would recommend him to anyone. I trust him!

Nov 14, 2025
HUNTSMAN CANCER INSTITUTE

I truly appreciate Dr. O'Neil's kindness and clarity as we discussed my situation. I was anxious and stressed so my questions weren't necessarily clear and focused. However, he was patient and very helpful as we discussed options and next steps in my treatment. I genuinely appreciated his candor and calm support. It mattered particularly at that time. I'm looking forward to being his patient and know that I will receive excellent care. That is very comforting.

Nov 14, 2025
HUNTSMAN CANCER INSTITUTE

Excellent.

Nov 02, 2025
HUNTSMAN CANCER INSTITUTE

My entire experience with Dr. O'Neil has been amazing. From his incredible skill as a surgeon to his excellent follow up and care.

Oct 31, 2025
HUNTSMAN CANCER INSTITUTE

Dr. O"Nell is the man I was needing to convince me, this surgery needs to be done now. He appears very clear eyed and honest. I immediately trusted him.

Oct 26, 2025
HUNTSMAN CANCER INSTITUTE

I would tell others about Dr. O'neil.

Oct 25, 2025
HUNTSMAN CANCER INSTITUTE

Caring, Competent and Professional. Answers all questions.

Oct 25, 2025
HUNTSMAN CANCER INSTITUTE

Dr O'Neal quickly diagnosed my condition and developed a treatment plan. He was very polite and respectful. He explained the recommended treatment to me in words I could understand.

Oct 17, 2025
HUNTSMAN CANCER INSTITUTE

Excellent Doctor. Very straightforward and provided the answers I needed

Oct 11, 2025
HUNTSMAN CANCER INSTITUTE

He is a very good listener. The examination was thorough.

Oct 07, 2025
HUNTSMAN CANCER INSTITUTE

He is great

Oct 04, 2025
HUNTSMAN CANCER INSTITUTE

I felt he was knowledge and was familiar with my concerns. I left his office feeling that I would be well taken care of.

Oct 03, 2025
HUNTSMAN CANCER INSTITUTE

I would highly recommend Dr. O'Neil. He was very knowledgeable and was very thorough explaining everything and all the options for treatment.

Sep 29, 2025
HUNTSMAN CANCER INSTITUTE

Thank you

Sep 19, 2025
HUNTSMAN CANCER INSTITUTE

Dr O'Neil is kind,courteous, and professional. He treats you with respect and concern with your health care needs.

Sep 14, 2025
HUNTSMAN CANCER INSTITUTE

Very concise in his evaluation and methods of treatment. Discusses the options and risks assocated with each.

Sep 06, 2025
HUNTSMAN CANCER INSTITUTE

Dr. Brock B O'Neil is caring and explains everything to me very well about his findings and options.

Aug 31, 2025
HUNTSMAN CANCER INSTITUTE

Dr O'Neil is solid yet personable; I couldn't ask for more in a doctor.

Aug 24, 2025
HUNTSMAN CANCER INSTITUTE

Caring and knowledgeable

Aug 23, 2025
HUNTSMAN CANCER INSTITUTE

I am impressed with his professional demeaner and curtesy to me as a patient. I would recommend him for anyone dealing with my type of illness.

Aug 14, 2025
HUNTSMAN CANCER INSTITUTE

Dr. O'Neil is a fantastic surgeon. If you are needing a physician with his specialty, you should definitely make an appointment with him!

Jul 19, 2025
HUNTSMAN CANCER INSTITUTE

Dr. O'Neil is a very quite but very intelligent. He does great work.

Jul 04, 2025
HUNTSMAN CANCER INSTITUTE

Dr O'Neil has been amazing! He was great to listen to our concerns and questions. Excellent treatment and follow-up care.

Jul 03, 2025
HUNTSMAN CANCER INSTITUTE

Very caring and very thorough about my treatment

Jun 28, 2025
HUNTSMAN CANCER INSTITUTE

A good doctor

Jun 26, 2025
HUNTSMAN CANCER INSTITUTE

Dr. O'Neil sends orders to a provider near us, checks on our carry-through, and is prepared to explain his findings. He takes time to ask if I have any questions. We appreciate not having to travel for tests and appointments.

Jun 08, 2025
HUNTSMAN CANCER INSTITUTE

I highly recommend Dr O'Neil. I have a lot of confidence in him.

Jun 06, 2025
HUNTSMAN CANCER INSTITUTE

Friendly, competent, highly skilled and caring surgeon.

Jun 06, 2025
HUNTSMAN CANCER INSTITUTE

No reservation of any kind recommending Brock O'Neil.

May 23, 2025
HUNTSMAN CANCER INSTITUTE

Dr. O'Neil is a fantastic doctor. He was great at explaining my diagnosis and how he can help. He is a top-notch physician and I would recommend him to anyone who needed the kinds of care he provides.

May 16, 2025
HUNTSMAN CANCER INSTITUTE

Very good care and thorough research and review of my medical information before I was seen I highly recommend

May 14, 2025
HUNTSMAN CANCER INSTITUTE

This man is a healer, who cares about his patients and the outcomes of his surgeries.

May 10, 2025
HUNTSMAN CANCER INSTITUTE

Very professional and knowledgeable !

May 08, 2025
HUNTSMAN CANCER INSTITUTE

The best

May 03, 2025
HUNTSMAN CANCER INSTITUTE

Very knowledgeable, attentive, and caring. I appreciate him lots and lots.

May 02, 2025
HUNTSMAN CANCER INSTITUTE

Very good surgeon and very likable person

Apr 26, 2025
HUNTSMAN CANCER INSTITUTE

Got to the point ,

Apr 26, 2025
HUNTSMAN CANCER INSTITUTE

Wonderful Nice Person

Apr 25, 2025
HUNTSMAN CANCER INSTITUTE

The best care ever

Apr 25, 2025
HUNTSMAN CANCER INSTITUTE

Very understanding and compassionate.

Apr 19, 2025
HUNTSMAN CANCER INSTITUTE

Great doctor

Apr 04, 2025
HUNTSMAN CANCER INSTITUTE

Very knowledgeable and caring

Mar 14, 2025
HUNTSMAN CANCER INSTITUTE

Awesome doctor! He is very caring and listens and answers questions. He gives the patients all their options and lets them decide what they want to do.

Mar 13, 2025
HUNTSMAN CANCER INSTITUTE

The best

Mar 10, 2025
HUNTSMAN CANCER INSTITUTE

Very professional

Feb 15, 2025
HUNTSMAN CANCER INSTITUTE

It was just a very short visit and conversation.

Feb 13, 2025
HUNTSMAN CANCER INSTITUTE

Dr O'Neil was very through and explained things very well.

Feb 08, 2025
HUNTSMAN CANCER INSTITUTE

He is caring and excellent at explaining what he recommends and why; he is not in a hurry to move on and makes you comfortable and confident in his skill.

Jan 25, 2025
HUNTSMAN CANCER INSTITUTE

Dr. O'Neil is a great professional with tremendous knowledge and experience in his field. If you are needing prostate cancer care, he is the one you want.

Jan 24, 2025
HUNTSMAN CANCER INSTITUTE

Good Doctor

Jan 24, 2025
HUNTSMAN CANCER INSTITUTE

He is exceptional in explaining diagnosis and treatments. He sits down and gives you his full attention. He answers all questions and makes sure you understand his answers. He doesn't act like he is in a hurry to leave. He understands that life changing decisions are being made and he wants to be sure his patients understand them

Jan 23, 2025
HUNTSMAN CANCER INSTITUTE

Very good.

Jan 15, 2025
HUNTSMAN CANCER INSTITUTE

extremely courteous and professional.

Jan 15, 2025
HUNTSMAN CANCER INSTITUTE

He is great normal no beard and a nice haircut. very patient oriented and knowledgeable

Dec 19, 2024
HUNTSMAN CANCER INSTITUTE

I had two procedures done by Dr. O'Neil and I felt on both occasions that I had received excellent care and had very successful outcomes.

Dec 13, 2024
HUNTSMAN CANCER INSTITUTE

Great doctor. Very professional.

Dec 12, 2024
HUNTSMAN CANCER INSTITUTE

Dr. O'Neil spent time explaining my condition and medical plan. He answered all of my questions. Thank you Dr. O'Neil.

Dec 12, 2024
HUNTSMAN CANCER INSTITUTE

Very good specialist and very professional [TRANSLATED]

Nov 22, 2024
HUNTSMAN CANCER INSTITUTE

He made me and my children feel very assured that the surgery was the best decision. Almost like a walk in the park.

Nov 16, 2024
HUNTSMAN CANCER INSTITUTE

He covers everything in a very professional and friendly manner

Nov 15, 2024
HUNTSMAN CANCER INSTITUTE

Very professional and straightforward

Nov 15, 2024
HUNTSMAN CANCER INSTITUTE

very excllent!!


Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

Board Certification and Academic Information

Academic Departments Surgery -Associate Professor
Academic Divisions Urology
Board Certification
American Board of Urology

Education history

Fellowship Urologic Oncology and Health Services Research - Vanderbilt University Fellow
Residency Urology - University of Utah Resident
Internship General Surgery - University of Utah Intern
Professional Medical Doctor of Medicine with Distinction in Research - University of Rochester School of Medicine & Dentistry M.D.
Undergraduate Exercise Science, Minor in Sociology - Brigham Young University B.S.

Selected Publications

Journal Article

  1. Galsky MD, Izadmehr S, Yu M, Curtis SD, Douville C, Popoli M, Ptak J, Dobbyn L, Silliman N, Chan KG, Dorff TB, Cetnar JP, ONeil B, DSouza A, Mamtani R, Kyriakopoulos CE, Brody R, Sadimin E, Mehrazin R, Chowell D, Sfakianos J, Daneshmand S, Pal SK, Bettegowda C, Kinzler KW, Papadopoulos N, Vogelstein B, Wang Y (2026). Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer. Proc Natl Acad Sci U S A, 123(8), e2533449123.
  2. Gore JL, Wolff EM, Nash MG, Comstock BA, Gilbert SM, Chang SS, Chisolm S, MacLean DB, Wright JL, Kates MR, Pohar KS, Guzzo TJ, Bivalacqua TJ, Nepple KG, Montgomery JS, Scarpato KR, Woldu SL, Master VA, Chen DYT, Mossanen M, Daneshmand S, ONeil BB, Tyson MD, Westerman ME, Kamat AM, Mansour AM, Chamie K, Riggs SB, Kukreja JB, Modi PK, Garg T, Peyton CC, Nix JW, Dickstein R, Gadzinski AJ, Sankin A, Shore ND, Lane BR, Bassett JC, Patel S, Morris DS, Macleod LC, Lee EK, Ritch CR, Follmer KM, Lee JR, Kim SM, Kessler LG, Smith AB, CISTO Collaborative group (2025). Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer. J Clin Oncol, JCO2501324.
  3. Murray NZ, Lumpkins CY, Al Awamlh BAH, Wallis C, Diehl C, Barocas DA, Beskow LM, ONeil B (2025). Drivers Influencing Prostate Cancer Treatment Decision making - A Qualitative Analysis of Underrepresented Men across the US. J Racial Ethn Health Disparities.
  4. Ou JY, Ramsay JM, Kaddas HK, VanDerslice JA, ONeil B, Garca SM, Horne BD, Hanson H, Kirchhoff AC (2025). Air Pollution and Cardiovascular Risks in Testicular Cancer Survivors: An Exploratory Case-Crossover Study. J Adolesc Young Adult Oncol, 15(1), 58-68.
  5. Lee H, Shen J, Fadlullah MZ, Neibling A, Hanson C, Ampaw E, Lin T, Larsen M, Lloyd J, Maughan BL, Swami U, Gupta S, Tward J, Johnson SB, ONeil B, Schmidt B, Dechet CB, Haaland B, Wang L, Tan AC, Kohli M (2025). Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer. Clin Proteomics, 22(1), 13.
  6. Lopez AA, Awamlh BAHA, Huang LC, Zhao Z, Koyama T, Hoffman KE, Wallis CJD, Cavanaugh K, Talwar R, Morgans AK, Goodman M, Hamilton AS, Wu XC, Li J, ONeil BB, Penson DF, Barocas DA (2024). Patient-reported functional outcomes and treatment-related regret in Hispanic and Spanish-speaking men following prostate cancer treatment. Urol Oncol, 43(4), 271.e19-271.e28.
  7. Ose DJ, Mark B, Ocier K, Adediran E, Taylor B, Svoboda K, Akerly W, ONeil B, Henry NL, Hashibe M (2024). Rural-Urban Disparities in Cancer Care-Analyzing Routinely Collected Patient-Reported Outcomes. A Cross-Sectional Study. Cancer Med, 14(8), e70437.
  8. Galarza Fortuna GM, Grass D, Maughan BL, Jain RK, Dechet C, Beck J, Schuetz E, Sanchez A, ONeil B, Poch M, Li R, Lloyd S, Tward J, Phunrab T, Hawks JL, Swami U, Boucher KM, Agarwal N, Gupta S (2025). Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT). J Immunother Cancer, 13(3).
  9. Chang Esther CP, Huang D, Lloyd S, Henry NL, ONeil B, Hashibe M (2025). Risks of adverse health outcomes among older rural prostate cancer survivors in the SEER-Medicare data. J Rural Health, 41(2), e70029.
  10. Choudry MM, Murray N, Dindinger-Hill K, Ambrose J, Hunt TC, Horns J, Martin C, Haaland B, Lowrance W, Hanson HA, Matern R, Cartwright PC, ONeil B (2024). Genitourinary cancer and family: The reverberating psychological and cardiovascular effects of a genitourinary cancer diagnosis on first-degree relatives and spouses. Cancer, 130(23), 4061-4070.
  11. Nguyen DD, Barocas DA, Zhao Z, Huang LC, Koyama T, Al Hussein Ai Awamlh B, Penson DF, Morgans AK, Goodman M, Hamilton AS, Wu XC, Li J, Paddock LE, Stroup AM, ONeil BB, Hoffman KE, Wallis CJD (2024). Association between smoking and prostate cancer survivors' long-term quality of life and function: an analysis of the CEASAR (Comparative Effectiveness Analysis of Surgery and Radiation) study. J Cancer Surviv.
  12. Dindinger-Hill K, Hu S, Hickman A, Choudry M, Vehawn J, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Kohli M, ONeil B, Schmidt B, Dechet C, Hashibe M, Sanchez A (2024). Association of Baseline Pre-Diagnosis and Post-Diagnosis Obesity and Weight Change with Cardiovascular Risk and Survival Among Nonmetastatic Prostate Cancer Survivors. Clin Genitourin Cancer, 22(3), 102057.
  13. Dindinger-Hill K, Horns J, Ambrose J, Vehawn J, Choudry M, Hunt TC, Chipman J, Haaland B, Li J, Hanson HA, ONeil B (2024). Effect of Health Service Area on Primary Care Physician Provision of Low-Value Cancer Screening. Ann Intern Med, 177(5), 583-591.
  14. Choudry M, Dindinger-Hill K, Ambrose J, Horns J, Vehawn J, Gill H, Murray NZ, Hunt TC, Martin C, Haaland B, Chipman J, Hanson HA, ONeil BB (2024). Urban relatives ameliorate survival disparities for genitourinary cancer in rural patients. Cancer Med, 13(5), e7058.
  15. Al Hussein Al Awamlh B, Wallis CJD, Penson DF, Huang LC, Zhao Z, Conwill R, Talwar R, Morgans AK, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, ONeil BB, Koyama T, Hoffman KE, Barocas DA (2024). Functional Outcomes After Localized Prostate Cancer Treatment. JAMA, 331(4), 302-317.
  16. Gore JL, Follmer K, Reynolds J, Nash M, Anderson CB, Catto JWF, Chamie K, Daneshmand S, Dickstein R, Garg T, Gilbert SM, Guzzo TJ, Kamat AM, Kates MR, Lane BR, Lotan Y, Mansour AM, Master VA, Montgomery JS, Morris DS, Nepple KG, ONeil BB, Patel S, Pohar K, Porten SP, Riggs SB, Sankin A, Scarpato KR, Shore ND, Steinberg GD, Strope SA, Taylor JM, Comstock BA, Kessler LG, Wolff EM, Smith AB (2023). Interruptions in bladder cancer care during the COVID-19 public health emergency. Urol Oncol.
  17. Hu S, Chang CP, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Haaland B, Porucznik CA, Gren LH, Sanchez A, Lloyd S, ONeil B, Hashibe M (2023). Mental health outcomes in a population-based cohort of patients with prostate cancer. J Natl Cancer Inst, 116(3), 445-454.
  18. Nielsen S, ONeil B, Chang CP, Mark B, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Henry NL, Lloyd S, Hashibe M (2023). Determining the association of rurality and cardiovascular disease among prostate cancer survivors. Urol Oncol, 41(10), 429.e15-429.e23.
  19. Huang D, Chang CE, Newman M, Deshmukh V, Snyder J, Date A, Galvao C, Lloyd S, Henry NL, ONeil B, Hashibe M (2023). Adverse health outcomes among rural prostate cancer survivors: A population-based study. Cancer Epidemiol, 86, 102430.
  20. Lange SM, Vehawn J, Choudry MM, Ambrose JP, Cluff CM, Haaland BA, Paudel N, Chipman J, Hanson HA, ONeil BB (2023). Low-Value Prostate Cancer Screening Among Young Men With Private Insurance. Urol Pract, 101097UPJ0000000000000461.
  21. Hu S, Chang CP, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Porucznik CA, Gren LH, Sanchez A, Lloyd S, Haaland B, ONeil B, Hashibe M (2023). Comparing Active Surveillance and Watchful Waiting With Radical Treatment Using Machine Learning Models Among Patients With Prostate Cancer. JCO Clin Cancer Inform, 7, e2300083.
  22. ONeil B, Dindinger-Hill K, Gill H, Coombs L, Haaland B, Ying J, Nelson RE, McPherson J, Kirchhoff AC, Ulrich CM, Huber J, Beck A, Mooney K (2023). Cost and Utilization Outcomes in Huntsman at Home, a Novel Oncology Hospital at Home Program. J Am Med Dir Assoc, 25(4), 610-613.
  23. Harper J, Hunt T, Choudry M, Kapron AL, Cooney KA, Martin C, Ambrose J, ONeil B (2023). Clinician interest in clinical decision support for PSA-based prostate cancer screening. Urol Oncol, 41(3), 145.e17-145.e23.
  24. Tallman JE, Wallis CJD, Zhao Z, Huang LC, Penson DF, Koyama T, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Hoffman KE, Barocas DA (2022). Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer. Prostate Cancer Prostatic Dis.
  25. De B, Pasalic D, Barocas DA, Wallis CJD, Huang LC, Zhao Z, Koyama T, Tang C, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman KE (2022). Reply by Authors. J Urol, 208(6), 1239.
  26. Samora NL, Wallis CJD, Huang LC, Tallman JE, Zhao Z, Hoffman K, Morgans A, Cooperberg M, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Kaplan S, ONeil B, Paddock LE, Stroup A, Wu XC, Koyama T, Penson DF, Barocas DA (2022). Association between body mass index and localized prostate cancer management and disease-specific quality of life. BJUI Compass, 4(2), 223-233.
  27. Lange SM, Choudry MM, Hunt TC, Ambrose JP, Haaland BA, Lowrance WT, Hanson HA, ONeil BB (2022). Impact of choosing wisely on imaging in men with newly diagnosed prostate cancer. Urol Oncol.
  28. Joyce DD, Wallis CJD, Huang LC, Hoffman KE, Zhao Z, Koyama T, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2022). The Association between Financial Toxicity and Treatment Regret in Men with Localized Prostate Cancer. JNCI Cancer Spectr.
  29. Harper JB, Greenberg SE, Hunt TC, Cooney KA, ONeil BB (2022). Initial outcomes and insights from a novel high-risk prostate cancer screening clinic. Prostate.
  30. De B, Pasalic D, Barocas DA, Wallis CJD, Huang LC, Zhao Z, Koyama T, Tang C, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman KE (2022). Patient-Reported Outcomes after External Beam Radiotherapy with Low Dose-Rate Brachytherapy Boost versus Radical Prostatectomy for Localized Prostate Cancer: Five-Year Results from a Prospective Comparative Effectiveness Study. J Urol, 101097JU0000000000002902.
  31. Hutten R, Khouri A, Parsons M, Tward A, Wilson T, Peterson J, Morrell G, Dechet C, ONeil B, Schmidt B, Kokeny K, Lloyd S, Cannon D, Tward J, Sanchez A, Johnson S (2022). The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer. Clin Genitourin Cancer, 20(6), e453-e459.
  32. Tallman JE, Wallis CJD, Huang LC, Zhao Z, Penson DF, Koyama T, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Barocas DA, Hoffman KE (2022). Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer. Prostate Cancer Prostatic Dis.
  33. Vehawn J, ONeil B (2021). Identifying Top Talent to Improve Prostatectomy Sexual Outcomes: Is the Juice Worth the Squeeze? JAMA Surg, 157(2), 144-145.
  34. Luckenbaugh AN, Wallis CJD, Huang LC, Wittmann D, Klaassen Z, Zhao Z, Koyama T, Laviana AA, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Hoffman KE, Penson DF, Barocas DA (2022). Association Between Treatment for Localized Prostate Cancer and Mental Health Outcomes. J Urol, 207, 101097JU0000000000002370.
  35. Wallis CJD, Zhao Z, Huang LC, Penson DF, Koyama T, Kaplan SH, Greenfield S, Luckenbaugh AN, Klaassen Z, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Hoffman KE, Barocas DA (2021). Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer. JAMA Oncol, 8(1), 50-59.
  36. Slade AD, Cardinal JR, Martin CR, Presson AP, Allen CD, Lowrance WT, Dechet CB, ONeil BB (2021). Feasibility of wearable activity trackers in cystectomy patients to monitor for postoperative complications. Curr Urol, 15(4), 209-213.
  37. Hunt TC, Ambrose JP, Haaland B, Kawamoto K, Dechet CB, Lowrance WT, Hanson HA, ONeil BB (2021). Decision fatigue in low-value prostate cancer screening. Cancer, 127(18), 3343-3353.
  38. Dorff TB, ONeil B, Hoffman KE, Lin DW, Loughlin KR, DallEra M (2021). 25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. Urol Oncol, 39(9), 521-527.
  39. Mooney K, Titchener K, Haaland B, Coombs LA, ONeil B, Nelson R, McPherson JP, Kirchhoff AC, Beck AC, Ward JH (2021). Evaluation of Oncology Hospital at Home: Unplanned Health Care Utilization and Costs in the Huntsman at Home Real-World Trial. J Clin Oncol, 39(23), 2586-2593.
  40. Wallis CJD, Huang LC, Zhao Z, Penson DF, Koyama T, Conwill R, Tallman JE, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Barocas DA, Hoffman KE (2021). Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: An assessment of the comparative effectiveness analysis of surgery and radiation (CEASAR) cohort. Urol Oncol, 40, 56.e1-56.e8.
  41. Pasalic D, Barocas DA, Huang LC, Zhao Z, Koyama T, Tang C, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup AM, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman KE (2021). Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer. Cancer, 127(11), 1912-1925.
  42. Greenberg SE, Hunt TC, Ambrose JP, Lowrance WT, Dechet CB, ONeil BB, Tward JD (2021). Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion. JCO Precis Oncol, 5.
  43. Stone BV, Laviana AA, Luckenbaugh AN, Huang LC, Zhao Z, Koyama T, Conwill R, Hoffman K, Joyce DD, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2020). Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer. J Urol, 205(3), 761-768.
  44. Lange SM, Ambrose JP, Flynn MC, Lowrance WT, Hanson HA, ONeil BB (2021). Prostate-specific antigen testing among young men: an opportunity to improve value. Cancer Med, 10(6), 2075-2079.
  45. Reisz PA, Laviana AA, Zhao Z, Huang LC, Koyama T, Conwill R, Hoffman K, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2020). Assessing the Quality of Surgical Care for Clinically Localized Prostate Cancer: Results from the CEASAR Study. J Urol, 204(6), 1236-1241.
  46. Huelster HL, Laviana AA, Joyce DD, Huang LC, Zhao Z, Koyama T, Hoffman KE, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg M, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2020). Radiotherapy after radical prostatectomy: Effect of timing of postprostatectomy radiation on functional outcomes. Urol Oncol, 38(12), 930.e23-930.e32.
  47. Klett DE, ONeil B (2020). Transurethral Resection of a Bladder Tumor in Pregnancy: Decidual Reaction Bladder Endometriosis. J Endourol Case Rep, 6(3), 132-134.
  48. Laviana AA, Zhao Z, Huang LC, Koyama T, Conwill R, Hoffman K, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2020). Development and Internal Validation of a Web-based Tool to Predict Sexual, Urinary, and Bowel Function Longitudinally After Radiation Therapy, Surgery, or Observation. Eur Urol, 78(2), 248-255.
  49. Tward JD, ONeil B, Boucher K, Kokeny K, Lowrance WT, Lloyd S, Cannon D, Stephenson RA, Agarwal N, Farr T, Petragallo R, Sherar NZ, Kunz I, Hofer A, Courdy S, Shrieve DC, Dechet C (2020). Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. Clin Genitourin Cancer, 18(4), 274-283.e5.
  50. Armstrong JM, Martin CR, Dechet C, Morton K, Evans D, Ambrose J, Maughan BL, ONeil B, Lowrance W (2020). 18F-fluciclovine PET CT detection of biochemical recurrent prostate cancer at specific PSA thresholds after definitive treatment. Urol Oncol, 38(7), 636.e1-636.e6.
  51. Leiser CL, Taddie M, Hemmert R, Richards Steed R, VanDerslice JA, Henry K, Ambrose J, ONeil B, Smith KR, Hanson HA (2020). Spatial clusters of cancer incidence: analyzing 1940 census data linked to 1966-2017 cancer records. Cancer Causes Control, 31(7), 609-615.
  52. Oswald N, Lin T, Haaland B, Flynn M, Kawamoto K, Cooney KA, Lowrance W, Hanson HA, ONeil B (2020). Factors associated with appropriate and low-value PSA testing. Cancer Epidemiol, 66, 101724.
  53. Leiser CL, Anderson RE, Martin C, Hanson HA, ONeil B (2020). Combining Drive Time and Urologist Density to Understand Access to Urologic Care. Urology, 139, 78-83.
  54. Hanson HA, Leiser CL, ONeil B, Martin C, Gupta S, Smith KR, Dechet C, Lowrance WT, Madsen MJ, Camp NJ (2020). Harnessing Population Pedigree Data and Machine Learning Methods to Identify Patterns of Familial Bladder Cancer Risk. Cancer Epidemiol Biomarkers Prev, 29(5), 918-926.
  55. Jalali A, Martin C, Nelson RE, Vanneman ME, Martin BI, Cooney KA, Waitzman NJ, ONeil B (2019). Provider Practice Competition and Adoption of Medicare's Oncology Care Model. Med Care, 58(2), 154-160.
  56. Hoffman KE, Penson DF, Zhao Z, Huang LC, Conwill R, Laviana AA, Joyce DD, Luckenbaugh AN, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Koyama T, Barocas DA (2020). Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA, 323(2), 149-163.
  57. Laviana AA, Hernandez A, Huang LC, Zhao Z, Koyama T, Conwill R, Hoffman K, Feurer ID, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2019). Interpretation of Domain Scores on the EPIC-How Does the Domain Score Translate into Functional Outcomes? J Urol, 202(6), 1150-1158.
  58. Hanson HA, Martin C, ONeil B, Leiser CL, Mayer EN, Smith KR, Lowrance WT (2019). The Relative Importance of Race Compared to Health Care and Social Factors in Predicting Prostate Cancer Mortality: A Random Forest Approach. J Urol, 202(6), 1209-1216.
  59. Nappi L, Thi M, Lum A, Huntsman D, Eigl BJ, Martin C, ONeil B, Maughan BL, Chi K, So A, Black PC, Gleave M, Wyatt AW, Lavoie JM, Khalaf D, Bell R, Daneshmand S, Hamilton RJ, Leao RRN, Nichols C, Kollmannsberger C (2019). Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. J Clin Oncol, 37(33), 3090-3098.
  60. Martin C, Haaland B, Tward AE, Dechet C, Lowrance W, Stephenson RA, Hanson H, ONeil B (2018). Describing the Spectrum of Patient Reported Outcomes after Radical Prostatectomy: Providing Information to Improve Patient Counseling and Shared Decision Making. J Urol, 201(4), 751-758.
  61. Tward JD, Poppe MM, Hitchcock YJ, ONeil B, Albertson DJ, Shrieve DC (2018). Demographics, stage distribution, and relative roles of surgery and radiotherapy on survival of persons with primary prostate sarcomas. Cancer Med, 7(12), 6030-6039.
  62. ONeil B, Hoffman KE, Koyama T, Alvarez JR, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Kaplan SH, Hashibe M, Stanford JL, Stroup AM, Paddock LE, Chen V, Wu XC, Resnick MJ, Penson DF, Barocas DA (2017). Patient Reported Comparative Effectiveness of Contemporary Intensity Modulated Radiation Therapy Versus External Beam Radiation Therapy of the Mid 1990s for Localized Prostate Cancer. Urol Pract, 5(6), 471-479.
  63. ONeil B, Martin C, Kapron A, Flynn M, Kawamoto K, Cooney KA (2018). Defining low-value PSA testing in a large retrospective cohort: Finding common ground between discordant guidelines. Cancer Epidemiol, 56, 112-117.
  64. Martin C, Leiser CL, ONeil B, Gupta S, Lowrance WT, Kohlmann W, Greenberg S, Pathak P, Smith KR, Hanson HA (2017). Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. J Natl Cancer Inst, 110(5), 527-533.
  65. ONeil B, Tyson M, Graves AJ, Barocas DA, Chang SS, Penson DF, Resnick MJ (2017). The influence of provider characteristics and market forces on response to financial incentives. Am J Manag Care, 23(11), 662-667.
  66. ONeil B, Maughan B (2017). A More Common Massive Retroperitoneal Mass. JAMA Surg, 152(8), 802-803.
  67. Sohn W, Graves AJ, Tyson MD, ONeil BB, Chang SS, Ni D, Barocas DA, Penson DF, Resnick MJ (2016). An Empiric Evaluation of the Effect of Variation in Intensity of Follow-Up for Surgically Treated Renal Neoplasms: Estimating Value in Survivorship Care. J Urol.
  68. ONeil B, Koyama T, Alvarez J, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, Stanford JL, Stroup AM, Paddock LE, Wu XC, Stephenson RA, Resnick MJ, Barocas DA, Penson DF (2015). The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. J Urol, 195(2), 321-9.
  69. ONeil BB, Graves AJ, Barocas DA, Chang SS, Penson DF, Resnick MJ (2015). Doing More for More: Unintended Consequences of Financial Incentives for Oncology Specialty Care. J Natl Cancer Inst, 108(2).
  70. ONeil BB, Koyama T, Alvarez J, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, Stanford JL, Stroup AM, Paddock LE, Wu XC, Stephenson RA, Resnick MJ, Barocas DA, and Penson DF (2015). The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. J Urol, 196.
  71. ONeil BB, Presson A, Gannon J, Stephenson RA, Lowrance W, Dechet CB, Tward JD, Myers JB, Brant WO (2014). Climacturia after definitive treatment of prostate cancer. J Urol, 191(1), 159-63.

Review

  1. Lange S, ONeil B (2021). Increasing the value of PSA through improved implementation. [Review]. Urol Oncol.

Conference Proceedings

  1. Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, ONeil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG (2020). Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol, United States, 38(24), 2798-2811.

Editorial

  1. Tingey S, Gangwish D, ONeil B (2025). Data Grow in Support of Micro-Ultrasound for Prostate Cancer Diagnosis. J Urol, 215(2), 142-143.
  2. Filon M, ONeil B (2024). Can We Be Less Active in Prostate Cancer Surveillance? J Urol, 213(1), 3-4.
  3. Hunt TC, ONeil BB (2020). Leveraging Behavioral Economics to Reduce Low-value Prostate Cancer Screening. Eur Urol, 77(4), 400-402.

Letter

  1. Hanson HA, Martin C, Leiser CL, ONeil B, Smith KR (2018). Response to K. Hemminki et al. [Letter to the editor]. J Natl Cancer Inst, 110(11), 1279.
  2. ONeil B, Lowrance WT, Heilbrun ME (2017). PET Scans With 18F-Fluorodeoxyglucose to Diagnose Adrenal Tumors. [Letter to the editor]. JAMA, 318(16), 1614.

Abstract

  1. ONeil B, Anderson R, Martin C, Leiser C, Hanson H (2019). A Novel Approach to Identify Disparities in Access to Urologic Care Based Upon Driving TIme [Abstract].
  2. Greenberg S, Tward J, Cooney K, Pappas L, ONeil B (2019). Germline genetic testing in men with prostate cancer: clinical characteristics and testing outcomes in a newly indicated population [Abstract].
  3. Armstrong J, Martin C, ONeil B, Dechet C, Morton K, Lowrance W (2018). Fluciclovine PET CT Detection of Biochemical Recurrent Prostate Cancer at Specific PSA Thresholds After Definitive Treatment [Abstract]. WSAUA.
  4. Jalali A, Nelson R, Vanneman M, Martin C, Martin B, Waitzman N, ONeil BB (06/25/2018). Provider Practice Competition and Adoption of Medicare's Oncology Care Model [Abstract]. AcademyHealth.
  5. Hanson H, Leiser C, Martin C, ONeil BB, Lowrance W, Alter O, Gupta S, Kohlman W, Greenberg W, Smith K, Camp N (04/2018). Redefining the Bladder Cancer Phenotype Using Patterns of Familial Risk [Abstract]. Journal of Urology, 199(4).
  6. Martin C, ONeil BB, Kapron A, Kawamoto K, Lowrance W, Flynn M, Cooney K (04/01/2018). Rate of Discordant PSA Testing Among Varied Guidelines: Identifying Targetable Inefficiencies in Our Health System [Abstract]. Journal of Urology, 199(4).
  7. Martin CM, ONeil BB, Kapron A, Flynn M, Kawamoto K, Lowrance WT, Cooney K (2017). Measuring PSA Screening Quality at the Health System Level: Potental Areas for Improvement [Abstract]. Society of Urologic Oncology.